Former Genzyme office in Framingham sells for $3M
Photo | Google
11 Pleasant Street Connector in Framingham
A 25,000-square-foot office building in Framingham that formerly housed the drugmaker Genzyme has sold for $3.2 million.
The buyer is a limited liability corporation, called 11 Pleasant Street Connector, LLC, which is registered in Palm Springs, Fla. The registered manager of that entity is Kirill Vesselov, who is CEO of Haven Health Management, which is also based in Palm Springs, Fla.
It was sold by Fafard Commercial Real Estate of Milford. The sale closed March 15. The 1.6-acre site at 9-11 Pleasant Street Connector was last assessed by the City of Framingham at roughly $3.3 million.
The office building at 9 and 11 Pleasant Street Connector is one of a few MetroWest office buildings that Genzyme has left in the past few years, along with 1 Research Drive in Westborough. An adjacent building at 15 Pleasant Street Connector that Genzyme left in 2012 was bought by U-Haul for $4.4 million in 2018 for a storage facility.
Genzyme is part of the French firm Sanofi, which is consolidating much of its Boston-area operations in a new building near Kendall Square in Cambridge. Sanofi has committed to keeping its Framingham presence, including sprawling facilities at 8 New York Ave. and 74 New York Ave.
Genzyme sold two of its Framingham offices, at 1-5 Mountain Road, in 2019 for about $20.5 million to the Carlyle Group, an international investment firm. Genzyme said at the time it would remain at the offices in a sale-leaseback agreement. The two Mountain Road buildings were then sold again the following year, along with a lab building 33 New York Ave., for $151 million to Oxford Properties, a Canadian real estate firm.
A Genzyme operations center at 11 Forbes Road in Northborough, where the company has a lease, was sold in February for $33 million to Boston's Camber Development and real estate investment firm Wheelock Street Capital, which has offices in Boston and Greenwich, Conn.
WBJ Web Partners
Most Recent
Most Recent
0 Comments